Has Chemo Pharma Lab declared dividend?

No Dividend History Available

Who are the peers of the Chemo Pharma Lab?

Chemo Pharma Lab's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Phaarmasia, Desh Rakshak, Parmax Pharma, and Saroja Pharma In. Notably, Desh Rakshak has the highest 1-year return at 422.50%, while Phaarmasia has the lowest at -24.74%, with Chemo Pharma Lab's return at 95.75%.

Peers: The peers of Chemo Pharma Lab are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Phaarmasia, Desh Rakshak, Parmax Pharma, and Saroja Pharma In.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Saroja Pharma In, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Growth is excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted at Divi's Lab., Torrent Pharma, Phaarmasia, Desh Rakshak, Parmax Pharma, and the rest. Excellent capital structure is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good capital structure is found at Torrent Pharma, and Below Average capital structure is noted at Divi's Lab., Phaarmasia, Desh Rakshak, Parmax Pharma, and Saroja Pharma In.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Desh Rakshak at 422.50%, while the peer with the lowest is Phaarmasia at -24.74%. Chemo Pharma Lab's own 1-year return is 95.75%, which is significantly higher than Phaarmasia's but lower than Desh Rakshak's. Additionally, Phaarmasia and Parmax Pharma have negative six-month returns.

Is Chemo Pharma Lab overvalued or undervalued?

As of April 25, 2023, Chemo Pharma Lab is considered a risky investment due to its overvaluation indicated by a PE ratio of 19.25, negative EV to EBIT and EBITDA, and a low ROCE of -3.04%, especially when compared to its peers, and it has recently underperformed the market with a one-week return of -9.53%.

As of 25 April 2023, Chemo Pharma Lab's valuation grade has moved from does not qualify to risky, indicating a shift in its perceived investment quality. The company appears to be overvalued based on its current metrics, particularly with a PE ratio of 19.25 and a negative EV to EBIT and EV to EBITDA of -12.50. Additionally, the ROCE stands at -3.04%, which raises concerns about its operational efficiency.<BR><BR>In comparison to its peers, Chemo Pharma Lab's valuation is notably less attractive. For instance, Altius Telecom, categorized as very attractive, has a PE ratio of 52.97, while other peers like Embassy Off.REIT and Inventurus Knowl are deemed very expensive with PE ratios of 23.06 and 56.63, respectively. Chemo Pharma Lab's stock has underperformed recently, with a one-week return of -9.53% compared to a 1.41% gain in the Sensex, further supporting the notion that it is currently overvalued.

What is the technical trend for Chemo Pharma Lab?

As of March 17, 2025, Chemo Pharma Lab's technical trend is bullish, supported by strong upward momentum from the MACD and KST, despite mixed signals from other indicators.

As of 17 March 2025, the technical trend for Chemo Pharma Lab has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting a strong upward momentum. The KST also confirms this bullish stance on both time frames. While the RSI shows no signal, the Bollinger Bands indicate a mildly bullish trend on both weekly and monthly charts. The daily moving averages are mildly bullish, suggesting some short-term strength. Overall, the current technical stance is bullish with a strong momentum indicated by the MACD and KST, despite some mixed signals from other indicators.

Who are in the management team of Chemo Pharma Lab?

As of March 2023, the management team of Chemo Pharma Lab includes Ashok Somani (Executive Director & CFO), Toby Antony (Independent Director), Shanta Somani (Non-Executive Director), Mathura Prasad Sharma (Independent Director), Bhavin Sheth (Director & CEO), Nandkumar Pareek (Independent Director), and Unnatti Jain (Company Secretary & Compliance Officer). These individuals oversee the company's governance and operations.

As of March 2023, the management team of Chemo Pharma Lab includes the following individuals:<BR><BR>1. Ashok Somani - Executive Director & CFO<BR>2. Toby Antony - Independent Director<BR>3. Shanta Somani - Non Executive Director<BR>4. Mathura Prasad Sharma - Independent Director<BR>5. Bhavin Sheth - Director & Chief Executive Officer<BR>6. Nandkumar Pareek - Independent Director<BR>7. Unnatti Jain - Company Secretary & Compliance Officer<BR><BR>These members play various roles within the company, contributing to its governance and operational management.

What does Chemo Pharma Lab do?

Chemo Pharma Laboratories Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology sector, established in 1942, currently reporting a net profit of -3 Cr for Q1 2025 and a market cap of INR 17 Cr. Key financial metrics include a P/E of 18.00 and a debt-equity ratio of -0.49.

Overview:<BR>Chemo Pharma Laboratories Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, focusing on pharmaceuticals and bulk drugs.<BR><BR>History:<BR>Established in August 1942, Chemo Pharma Laboratories has undergone significant changes, including the disposal of its business due to increased competition. The latest financial report indicates a net profit of -3 Cr for the quarter ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: -3 Cr (Quarterly Results - Mar 2025)<BR>Market-cap value: INR 17 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 18.00<BR>Industry P/E: 32<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.49<BR>Return on Equity: 2.56%<BR>Price-to-Book: 1.34<BR><BR>Contact Details:<BR>Address: 5 Kumud Apartment CHS Ltd, Karnik Road Chikan Ghar Kalyan Thane Maharashtra : 421301<BR>Phone: 91-022-22078381/22078382<BR>Email: chemopharmalab@gmail.com<BR>Website: http://www.thechemopharmalaboratoriesltd.com

Who are the top shareholders of the Chemo Pharma Lab?

The top shareholders of Chemo Pharma Lab are Citric India Ltd with 24.63% and Shree Consultation And Services Pvt Ltd with 3.63%. Individual investors own a combined 65.29%, with no mutual funds or foreign institutional investors currently holding shares.

The top shareholders of Chemo Pharma Lab include Citric India Ltd, which holds the highest promoter stake at 24.63%. Additionally, Shree Consultation And Services Pvt Ltd is the highest public shareholder with a holding of 3.63%. Individual investors collectively own 65.29% of the company. There are no mutual funds or foreign institutional investors currently holding shares in Chemo Pharma Lab.

How big is Chemo Pharma Lab?

As of 24th July, Chemo Pharma Laboratories Ltd has a market capitalization of 19.00 Cr, categorizing it as a Micro Cap company, with reported Net Sales of 0.00 Cr and a Net Profit of 0.35 Cr in the latest four quarters.

As of 24th July, Chemo Pharma Laboratories Ltd has a market capitalization of 19.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>In the latest four quarters, Chemo Pharma Laboratories Ltd reported Net Sales of 0.00 Cr and a Net Profit of 0.35 Cr.<BR><BR>The latest annual period for the balance sheet is March 2016, with Shareholder's Funds amounting to 3.67 Cr and Total Assets valued at 3.87 Cr.

When is the next results date for Starsource Multi?

The next results date for Starsource Multi is 13 November 2025.

The next results date for Starsource Multi is scheduled for 13 November 2025.

How has been the historical performance of Starsource Multi?

The historical performance of Starsource Multi for the year ending March 2016 was poor, with total operating income of 0.49 Cr, a loss before tax of -1.35 Cr, and a negative EPS of -9.66, indicating significant financial challenges. The company had total liabilities of 3.87 Cr against shareholder's funds of 3.67 Cr, reflecting a precarious financial position.

Answer:<BR>The historical performance of Starsource Multi for the year ending March 2016 shows a challenging financial situation with negative profitability and limited operational activity.<BR><BR>Breakdown:<BR>In March 2016, Starsource Multi reported total operating income of 0.49 Cr, derived primarily from other operating income, as net sales were recorded at 0.00 Cr. The total expenditure, excluding depreciation, amounted to 1.84 Cr, leading to an operating profit (PBDIT) of -1.35 Cr. Consequently, the profit before tax also stood at -1.35 Cr, resulting in a profit after tax of -1.45 Cr. The company had a negative earnings per share (EPS) of -9.66 and an operating profit margin of -273.78%. On the balance sheet, shareholder's funds totaled 3.67 Cr, with total liabilities at 3.87 Cr, indicating a precarious financial position. The cash flow from operating activities was -2.09 Cr, while cash flow from investing activities showed a positive inflow of 2.15 Cr, leading to a net cash inflow of 0.06 Cr by the end of the period, with closing cash and cash equivalents at 0.44 Cr.

Which are the latest news on Starsource Multi?

Which are the latest news on Starsource Multi?

Why is Starsource Multi falling/rising?

As of 21-Dec, Starsource Multitrade Ltd's stock price is at 107.00, down 0.88% and has declined 16.93% over the last four days. The stock is trading below all major moving averages, and investor participation has decreased significantly, indicating a bearish trend.

As of 21-Dec, Starsource Multitrade Ltd's stock price is falling, currently at 107.00, reflecting a change of -0.95 (-0.88%). The stock has been underperforming significantly, with a consecutive decline over the last four days, resulting in a total drop of -16.93% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>Investor participation has also decreased, as evidenced by a delivery volume of 447 on December 18, which is down by -46.39% compared to the 5-day average delivery volume. This decline in trading activity suggests reduced interest from investors, further contributing to the stock's downward movement. Overall, these factors indicate that Starsource Multitrade Ltd is experiencing a decline in its stock price.

Why is Starsource Multi falling/rising?

As of 22-Dec, Starsource Multitrade Ltd's stock price is rising to 117.50, up 11.64%. This increase follows a trend reversal after previous declines, but the stock has underperformed against the Sensex recently, raising concerns about liquidity and investor engagement despite positive year-to-date and long-term growth.

As of 22-Dec, Starsource Multitrade Ltd's stock price is rising, currently at 117.50, reflecting a change of 12.25 (11.64%) upward. This increase can be attributed to several factors. Firstly, the stock has experienced a trend reversal, gaining after four consecutive days of decline. Additionally, it opened with a significant gain of 9.26% today, indicating strong market interest. The stock also reached an intraday high of Rs 118.75, which is a 12.83% increase. <BR><BR>Despite the positive performance today, it is important to note that the stock has underperformed against the benchmark Sensex over the past week and month, with declines of 8.77% and 0.42%, respectively. However, its year-to-date performance remains positive at +6.97%, and it has shown substantial growth over the past year (+25.61%) and three years (+193.75%). <BR><BR>The stock's current performance is also characterized by a higher trading volume close to its low price, although there has been a notable decline in investor participation, with delivery volume dropping by 68.04% against the five-day average. This suggests that while the stock is experiencing a rise today, there are underlying concerns regarding liquidity and investor engagement. Overall, the combination of a trend reversal and today's strong opening has contributed to the stock's rise.

Why is Starsource Multitrade Ltd falling/rising?

As of 23-Dec, Starsource Multitrade Ltd's stock price is at 108.00, reflecting a decrease of 9.5 or 8.09%. The stock has underperformed significantly, showing high volatility and declining investor participation, which are contributing to its downward trend.

As of 23-Dec, Starsource Multitrade Ltd's stock price is falling, currently at 108.00, which reflects a decrease of 9.5 or 8.09%. The stock has underperformed significantly today, with a performance that is 7.97% lower than its sector. Although it opened with a gain of 2.13% and reached an intraday high of Rs 120, it also experienced a substantial drop, touching a low of Rs 105, which is a decline of 10.64%. <BR><BR>The stock has shown high volatility today, with an intraday volatility of 6.67%, indicating significant price fluctuations. Furthermore, it is trading below its moving averages across various time frames (5-day, 20-day, 50-day, 100-day, and 200-day), which typically signals bearish sentiment. <BR><BR>Additionally, there has been a notable decrease in investor participation, with delivery volume dropping by 37.38% compared to the 5-day average. This decline in trading activity suggests a lack of confidence among investors, contributing to the stock's downward movement. Overall, the combination of high volatility, underperformance relative to the sector, and falling investor participation are key factors driving the decline in Starsource Multitrade Ltd's stock price.

Why is Starsource Multitrade Ltd falling/rising?

As of 24-Dec, Starsource Multitrade Ltd's stock price is at 106.30, down 5.34% and significantly underperforming its sector. The stock has seen consecutive declines totaling 9.53% over the last two days and is trading below all major moving averages, indicating a bearish trend despite increased investor participation.

As of 24-Dec, Starsource Multitrade Ltd's stock price is falling, currently at 106.30, which reflects a decrease of 6.0 points or 5.34%. The stock has been underperforming significantly, with a performance today that is 5.48% lower than its sector. It has experienced consecutive declines over the last two days, totaling a drop of 9.53%. <BR><BR>Today, the stock opened with a loss of 6.01% and reached an intraday low of Rs 105.55, indicating a volatile trading session with a wide range of Rs 12.45. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which suggests a bearish trend. <BR><BR>Despite a notable increase in investor participation, with delivery volume rising by 511.22% compared to the 5-day average, the overall market sentiment remains negative, contributing to the stock's decline. The stock's year-to-date performance shows a loss of 3.22%, contrasting sharply with the Sensex, which has gained 9.30% over the same period.

Why is Starsource Multitrade Ltd falling/rising?

As of 25-Dec, Starsource Multitrade Ltd's stock price is at 106.30, down 5.34%, and has underperformed its sector by 5.48%. The stock has faced consecutive losses totaling 9.53% over the last two days and is trading below all key moving averages, indicating a bearish trend.

As of 25-Dec, Starsource Multitrade Ltd is experiencing a decline in its stock price, currently at 106.30, which reflects a change of -6.0 (-5.34%). The stock has been underperforming significantly, with a performance today that is -5.48% lower than its sector. It has also faced consecutive losses over the last two days, accumulating a total drop of -9.53% during this period.<BR><BR>The stock opened with a loss of -6.01% today and reached an intraday low of Rs 105.55, indicating a challenging trading environment. Additionally, Starsource Multitrade Ltd is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which suggests a bearish trend. The high volatility observed today, with an intraday volatility of 5.56%, further emphasizes the instability in the stock's performance.<BR><BR>Despite a notable rise in investor participation, with delivery volume increasing by 511.22% against the 5-day average, the overall market sentiment appears negative, contributing to the stock's decline. The stock's performance over the past week and month has also been poor, with declines of -9.03% and -7.48%, respectively, while the benchmark Sensex has shown positive returns during the same periods. This contrast highlights the stock's struggles relative to broader market trends.

Why is Starsource Multitrade Ltd falling/rising?

As of 26-Dec, Starsource Multitrade Ltd's stock price is declining at 106.30, down 0.23%, and has underperformed its sector by 5.48%. The stock is on a bearish trend, trading below all key moving averages, with a year-to-date decline of 3.22% compared to the Sensex's gain of 8.83%.

As of 26-Dec, Starsource Multitrade Ltd is experiencing a decline in its stock price, currently at 106.30, which reflects a change of -0.25 (-0.23%). The stock has underperformed its sector by 5.48% today and has been on a downward trend, having lost 9.53% over the last two days. It opened the day with a significant loss of 6.01% and reached an intraday low of Rs 105.55, indicating a volatile trading session with a wide range of Rs 12.45.<BR><BR>Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, further suggesting a bearish trend. Despite a notable increase in investor participation, with delivery volume rising by 511.22% against the 5-day average, the overall performance year-to-date shows a decline of 3.22%, contrasting sharply with the Sensex, which has gained 8.83% in the same period. This combination of factors contributes to the current downward movement in the stock price of Starsource Multitrade Ltd.